Indicated for: osteoporosis
Route of administration: oral
Substance: strontium ranelat (bone metabolism agent)
ATC: M05BX03 (Musculo-skeletal system | Drugs affecting bone structure and mineralization | Other drugs affecting bone structure and mineralization)
Strontium ranelate is a medication used for the treatment of severe osteoporosis in postmenopausal women and men at high risk of fractures. It works by stimulating bone formation and reducing bone resorption, thereby improving bone mineral density.
The medication is taken orally, usually once daily at bedtime, as directed by a doctor. It is important for patients to follow the prescribed dosage and avoid consuming foods or supplements containing calcium near the time of administration.
Patients should be aware of potential side effects, such as nausea, diarrhea, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, and headache. In rare cases, severe reactions such as venous thromboembolism or serious allergic reactions may occur. Patients should be informed of these risks before starting treatment.